Oral Solution Formulation of Namenda(R), the Only FDA-Approved Oral Solution for Moderate to Severe Alzheimer's Disease, Now Ava
August 18 2005 - 6:10PM
PR Newswire (US)
NEW YORK, Aug. 18 /PRNewswire-FirstCall/ -- Forest Laboratories,
Inc. (NYSE:FRX) announced today that an oral solution formulation
of Namenda(R)(memantine HCl), the only FDA-approved treatment for
moderate to severe Alzheimer's disease, is now available to
physicians, patients, and pharmacies nationwide. Oral solution
offers an alternative that may make administration of Namenda
easier for those patients who have trouble swallowing tablets, and
for those who prefer taking medication in liquid form. (Logo:
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) The oral
solution of Namenda is equivalent on a milligram per milligram
basis to the Namenda tablets and is administered in the same
manner. Namenda oral solution is available in a 2mg/ml
concentration, 360 ml (12 oz) bottle. About Namenda Namenda
(memantine HCl) is the first in a class of medications with a
unique mechanism of action that focuses on the glutamate pathway, a
target for the treatment of Alzheimer's disease. Indicated for the
treatment of moderate to severe Alzheimer's disease, the FDA
approved Namenda (October 2003) based on three studies of Namenda
used alone or in combination with another Alzheimer's disease drug.
Namenda is contraindicated in patients with known hypersensitivity
to memantine HCl or any excipients used in the formulation. The
most common adverse events reported with Namenda vs placebo
(greater-than or equal-to 5% and higher than placebo) were
dizziness, confusion, headache, and constipation. In patients with
severe renal impairment, the dosage should be reduced. About Forest
Laboratories and Its Products Forest Laboratories' growing line of
products includes: Lexapro(R) (escitalopram oxalate), an SSRI
antidepressant indicated for the initial and maintenance treatment
of major depressive disorder and for generalized anxiety disorder
in adults; Namenda(R)(memantine HCl), an N-methyl-D-aspartate
(NMDA)-receptor antagonist indicated for the treatment of moderate
to severe Alzheimer's disease; Benicar(R)*(olmesartan medoxomil),
an angiotensin receptor blocker indicated for the treatment of
hypertension; Benicar HCT(R)(olmesartan medoxomil
hydrochlorothiazide), an angiotensin receptor blocker and diuretic
combination product indicated for the second-line treatment of
hypertension; Campral(R)*(acamprosate calcium), a glutamate
receptor modulator, indicated for the maintenance of abstinence
from alcohol in patients with alcohol dependence who are abstinent
at treatment initiation in combination with psychosocial support;
and Combunox(TM)(Oxycodone HCl and Ibuprofen), an opioid and NSAID
combination indicated for the short-term management of acute,
moderate to severe pain. Except for the historical information
contained herein, this release contains "forward-looking
statements" within the meaning of the Private Securities Reform Act
of 1995. These statements are subject to risks and uncertainties
that affect our business, including risk factors listed from time
to time in the Company's SEC reports, including the Company's
Annual Report on Form 10-K for the fiscal year ended March 31, 2005
and on form 10-Q for the periods ended June 30, 2005. Actual
results may differ materially from those projected. * Benicar is a
registered trademark of Sankyo Pharma Inc.; Campral is a registered
trademark under license from Merck Sante s.a.s., subsidiary of
Merck KGaA, Darmstadt, Germany. Forest Laboratories markets
Namenda(R)(memantine HCl) in the United States under license from
Merz Pharma GmbH & Co. of Germany. Lundbeck, under license from
Merz, markets memantine as Ebixa(R), and Merz markets memantine as
Axura(R) and as Akatinol(R), each in a number of markets worldwide.
Ebixa, Axura, and Akatinol are registered trademarks Merz Pharma
GmbH & Co.
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGODATASOURCE:
Forest Laboratories, Inc. CONTACT: Charles Triano, Vice President,
Investor Relations of Forest Laboratories, Inc., +1-212-224-6714, ;
or Physician Contact: Professional Affairs, 1-800-678-1605 Ext.
7301, for Forest Laboratories Web site: http://www.frx.com/
Copyright
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024